is that TCRs can be finicky and laborious to manipulate, and it is not feasible to systematically explore the full combinatorial space of all binding loop sequences and lengths 7, 8 .
To overcome these limitations, Schmitt et al. 2 sought to coax T cells themselves to do the work of TCR diversification and selection by exploiting a quirk of T-cell development. Conventional αβ T cells, which comprise the large majority of a person's T-cell compartment, to the pruning of self-reactive T cells during development 5 . Researchers have succeeded in increasing TCR affinity by mutagenesis of the pMHC-contacting CDR loops, much as is done for antibodies. However, this approach can inadvertently create TCRs that crossreact against normal tissues, as highlighted by a recent case in which engineered TCR T cells specific to a melanoma antigen attacked cardiac tissue 6 . A second technical challenge When developing new therapies, borrowing from nature has an undeniable appeal. Solutions honed by millions of years of evolution are often better starting points than what scientists can come up with from scratch. This is the principle behind cancer immunotherapies based on engineered T-cell receptors (TCRs). Natural tumor-reactive TCRs are identified, molecularly modified to improve their function, and introduced into a patient's T cells 1 . But optimizing TCRs is still an imperfect technology, and the resulting T cells can have suboptimal activity against tumor cells and the potential for cross-reactivity against normal cells. In this issue, Schmitt et al. 2 present a system that borrows from the natural process of T-cell development to create better TCRs for cancer immunotherapies.
TCR-engineered T cells have several advantages over other immunotherapies. Unlike checkpoint blockade, which can nonspecifically unleash all T cells, they boost the immune response specifically against the tumor and do not require that the patient have pre-existing tumor-reactive T cells. And unlike T cells engineered to express chimeric antigen receptors (synthetic fusions of an extracellular antigen-binding domain and an intracellular T-cell-signaling domain), TCR-engineered T cells are not limited to targeting cell surface proteins because they interact with peptides that are derived from intracellular and extracellular proteins and are displayed on the cell surface by the major histocompatibility complex (MHC).
Although TCR-engineered T cells have shown promise in preclinical and clinical studies 1,3 , they have not yet joined the pantheon of commonly used immunotherapies. The chief technical challenge has been to increase the antitumor reactivity of engineered TCRs without introducing deleterious reactivity against healthy tissue. TCRs generally bind their peptide-MHC (pMHC) ligands with low affinity 4 , and tumor-specific T cells trend toward the lower end of the affinity range owing Tuning up T-cell receptors recombine their TCR α and β chains in discrete steps: TCRβ followed by TCRα. If a developing T cell successfully recombines its β chain, it receives weak functional signals that prompt progression to α-chain recombination and functional maturity 9 . However, if it receives an unexpectedly strong signal during early development, the cell responds as if it has recombined a TCR using the alternate γ and δ chains, and is diverted to an alternative γδ-T-cell-like developmental pathway 10 . Schmitt et al. 2 take advantage of the fact that triggering of the γδ pathway-and the associated strong signaling via the TCR-can be tracked with cell surface markers. Thus, T cells that carry a fully formed αβ TCR and signal at an earlier-than-expected stage of T-cell development after pMHC engagement can be readily isolated. The authors harness this process to select for strongly reactive, tumorantigen-specific TCRs (Fig. 1) . They introduce a recombined TCRα chain derived from a previously validated tumor-specific TCR into developing T cells and allow the cells to mature on feeder cells in the presence of the tumor antigen. Cells that show a strong TCR signal during TCRβ rearrangement are sorted, and their TCRβ chains are sequenced and tested to identify those that confer higher affinity than the parental one.
The authors demonstrate their method with a mouse antitumor TCR both in vitro and in vivo and with a human antitumor TCR in vitro using T-cell progenitors. They find that the T cells do indeed recombine TCRβ chains specific for the intended tumor antigens. As hoped, the isolated T cells contain a diverse collection of TCR Vβ regions and a collection of peptide-binding CDR3 loops that are diversified in both sequence and length. The newly generated TCRβ chains recognize the intended antigen, and some bind their antigens with higher affinity than the parental chain does and signal more potently.
When vetting a new TCR for clinical development, a chief concern is unwanted recognition of healthy cells expressing non-target antigens that are recognized by the tumor-specific TCR. This is a particular challenge because each TCR has its own cross-reactivity profile, and even extensive vetting against cell lines derived from multiple organs cannot rule out a negative interaction in patients. In principle, optimizing a TCR for better function through a native T-cell pathway while simultaneously conserving most of the TCR interface should mitigate potential cross-reactivity. Indeed, when tested for function, the newly identified TCRs show no signs of unwanted self-reactivity in a mouse model.
With the principle demonstrated, there are some considerations in moving the approach forward. First, the system optimizes only TCRβ chains, which account for half of the antigenbinding interface 4 , and reliance on the V(D)J recombination machinery imposes biases on the peptide-contacting junctions, limiting diversity. These issues may explain why the observed affinity gains were modest. Additionally, it remains to be seen whether the improvements observed in vitro translate into improved antitumor activity in vivo. Finally, while modifying only the peptide-binding CDR3 loops should help prevent peptide-independent reactivity, and limiting TCR selection to β chains with high germline-encoded similarity to the parental chain should help limit off-target reactivity, any improved TCR will have to undergo extensive vetting for cross-reactivity on the path to clinical development.
These caveats aside, the method of Schmitt et al. 2 could prove important for future TCR engineering efforts. In relying on T-cell development, it should be applicable to any TCR. It also eliminates much of the effort and TCRspecific optimizations of other methods. Having been generated by the natural diversification and signaling machinery, the resulting TCRs already pass several of the requirements for function and specificity needed for therapeutic applications.
